Malaysian Genomics Resource Centre Berhad

KLSE:MGRC Stock Report

Market Cap: RM 45.3m

Malaysian Genomics Resource Centre Berhad Valuation

Is MGRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MGRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MGRC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MGRC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MGRC?

Key metric: As MGRC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MGRC. This is calculated by dividing MGRC's market cap by their current revenue.
What is MGRC's PS Ratio?
PS Ratio4.6x
SalesRM 9.74m
Market CapRM 45.28m

Price to Sales Ratio vs Peers

How does MGRC's PS Ratio compare to its peers?

The above table shows the PS ratio for MGRC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
PLABS PeterLabs Holdings Berhad
0.3xn/aRM 48.2m
RHONEMA Rhone Ma Holdings Berhad
0.7x4.4%RM 149.3m
PBSV Pharma-Bio Serv
1.1x53.3%US$11.5m
PRM Proteome Sciences
2xn/aUK£8.1m
MGRC Malaysian Genomics Resource Centre Berhad
4.6xn/aRM 45.3m

Price-To-Sales vs Peers: MGRC is expensive based on its Price-To-Sales Ratio (4.6x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does MGRC's PS Ratio compare vs other companies in the Asian Life Sciences Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
MGRC 4.6xIndustry Avg. 4.2xNo. of Companies12PS02.85.68.411.214+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MGRC is expensive based on its Price-To-Sales Ratio (4.6x) compared to the Asian Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is MGRC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MGRC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MGRC's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies